Janux Therapeutics (NASDAQ:JANX) Stock Price Up 6.4%

Janux Therapeutics, Inc. (NASDAQ:JANX) rose 6.4% on Thursday . The stock traded as high as $22.86 and last traded at $22.86. Approximately 274 shares traded hands during trading, a decline of 100% from the average daily volume of 226,091 shares. The stock had previously closed at $21.48.

JANX has been the topic of several research analyst reports. Cowen initiated coverage on Janux Therapeutics in a research report on Tuesday, July 6th. They set an “outperform” rating on the stock. HC Wainwright initiated coverage on Janux Therapeutics in a research report on Tuesday, July 6th. They set a “buy” rating and a $35.00 price target on the stock. Zacks Investment Research raised Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Bank of America initiated coverage on Janux Therapeutics in a research report on Tuesday, July 6th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Evercore ISI initiated coverage on Janux Therapeutics in a research report on Tuesday, July 6th. They set an “outperform” rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $35.00.

The firm’s 50 day moving average is $27.60.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Tuesday, August 10th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.48). The business had revenue of $0.48 million during the quarter. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in JANX. Citigroup Inc. purchased a new stake in shares of Janux Therapeutics in the second quarter valued at approximately $2,163,000. BlackRock Inc. purchased a new stake in shares of Janux Therapeutics in the second quarter valued at approximately $2,743,000. FMR LLC purchased a new stake in shares of Janux Therapeutics in the second quarter valued at approximately $45,997,000. Vanguard Group Inc. purchased a new stake in shares of Janux Therapeutics in the second quarter valued at approximately $723,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Janux Therapeutics in the second quarter valued at approximately $549,000. Institutional investors own 59.46% of the company’s stock.

About Janux Therapeutics (NASDAQ:JANX)

Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

Featured Story: What is the Beige Book?

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.